Respiratory DisordersChromocell has a discovery program to identify compounds for the treatment of pulmonary pathologies. The target is an ion channel comprising three distinct subunits which has never been reduced to a cell based assay due to the toxicity of its over-expression. Modulation of this channel impacts several pulmonary conditions, including pulmonary edema, chronic bronchitis and cystic fibrosis. Applying Chromovert technology and a multi-pronged approach exploring various cell backgrounds and media formulations, we were able to isolate a functional and viable clonal cell line for this target. An HTS campaign has been carried out and hits were identified representing agonists, antagonists and positive modulators. The compounds are progressing through lead optimization, IND submission and clinical trials.
about chromovert
